Rhythm Pharmaceuticals Launches Imcivree (setmelanotide) for Obesity and Control of Hunger in Bardet-Biedl Syndrome in Germany
Shots:
- The company reported the commercial availability of Imcivree in Germany for the treatment of obesity & control of hunger associated with BBS. Imcivree is eligible for federal reimbursement by Statutory Health Insurances in Germany
- Imcivree is the first US FDA-approved & EC-authorized therapy that targets a root cause of hyperphagia and early-onset, severe obesity & also received marketing authorization from the EC for BBS and early-access authorization for setmelanotide in France in 2022
- The product is expected to launch in the Netherlands in 2023 for BBS and in Italy, Spain & the UK in 2024. The product is now available to patients in 9 global markets, incl. the US for POMC, PCSK1, or LEPR deficiency obesity and/or BBS
Ref: Rhythm | Image: Rhythm
Related News:- Rhythm’s Imcivree (setmelanotide) Receives EC’s Approval for the Treatment of Bardet-Biedl Syndrome
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
